Light Sedation or Intubated General Anesthesia in Patients With Brain Cancer Undergoing Craniotomy
NCT ID: NCT02193568
Last Updated: 2019-03-13
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
4 participants
INTERVENTIONAL
2014-04-30
2019-01-24
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Intravenous Anesthesia Versus Anesthesia With Volatile Agents in Elective Craniotomy for Tumors
NCT00555984
Assessment of Cognitive Functions and Quality of Life in Patients Undergoing Surgery for Supratentorial Brain Tumor
NCT02428972
Influences of Propofol and Sevoflurane Anesthesia in Brain Tumor
NCT05141877
Anesthesia Induced Brain Cancer Survival (ABC Survival): A Feasibility Study
NCT04962672
Study of the Depth of Anesthesia on Postoperative Clinical Outcome in Patients With Supratentorial Tumor
NCT03033693
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
I. To compare the overall hospital length of stay (LOS) in patients undergoing craniotomy with light sedation vs. general anesthesia.
SECONDARY OBJECTIVES:
I. To compare resource utilization between the two groups. II. To assess the frequency of post-operative delirium. III. To measure patient perceptions. IV. To track patient complications during hospital stay - nausea/vomiting, pain, hematology/lab stability, hemodynamic stability.
V. To track re-admission and extended hospital stay rates. VI. To compare cost of both approaches.
OUTLINE: Patients are randomized to 1 of 2 arms.
ARM I: Patients receive light sedation (awake) and undergo craniotomy.
ARM II: Patients receive intubated general anesthesia and undergo craniotomy.
After completion of study, patients are followed up at 1month and 1 year.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
SUPPORTIVE_CARE
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Arm I (light sedation)
Patients receive light sedation (awake) and undergo craniotomy.
Arm I (light sedation)
If patients experience excessive preoperative anxiety they will receive light sedation of midazolam 1 mg IV.In our standard practice, it is very rare that patients receive anxiolytic premedication for craniotomies, so it is unlikely that many will require midazolam. Two IVs will be placed, one for infusion of meds and one for possible resuscitation.
Arm II (intubated general anesthesia)
Undergo craniotomy
Arm II (intubated general anesthesia)
Ancillary studies
Arm I (light sedation)
Undergo craniotomy
Arm I (light sedation)
Ancillary studies
Arm II (intubated general anesthesia)
Patients receive intubated general anesthesia and undergo craniotomy.
Arm II (intubated general anesthesia)
Receive intubated general anesthesia
Arm II (intubated general anesthesia)
Undergo craniotomy
Arm II (intubated general anesthesia)
Ancillary studies
Arm I (light sedation)
Undergo craniotomy
Arm I (light sedation)
Ancillary studies
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Arm I (light sedation)
If patients experience excessive preoperative anxiety they will receive light sedation of midazolam 1 mg IV.In our standard practice, it is very rare that patients receive anxiolytic premedication for craniotomies, so it is unlikely that many will require midazolam. Two IVs will be placed, one for infusion of meds and one for possible resuscitation.
Arm II (intubated general anesthesia)
Receive intubated general anesthesia
Arm II (intubated general anesthesia)
Undergo craniotomy
Arm II (intubated general anesthesia)
Ancillary studies
Arm I (light sedation)
Undergo craniotomy
Arm I (light sedation)
Ancillary studies
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Elective craniotomy for supratentorial brain tumors
* Primary brain cancer (presumed gliomas with no radiographic or clinical evidence of metastatic disease to the brain)
* First craniotomy
* American Society of Anesthesiologists (ASA) I-III
* Body mass index (BMI) \< 35
Exclusion Criteria
* Traumatic lesions/hematomas
* Emergency case
* Systemic disease burden with metastatic tumor to the brain
* Presence of medical co-morbidities, which, in the opinion of the investigator complicates the surgical procedure or would require additional hospital stay
* Necessity of awake procedure requiring intraoperative participation of patient due to the presence of the lesion in eloquent brain areas
* Prisoners
* Pregnant women
19 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Ohio State University Comprehensive Cancer Center
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
James Elder
Principal Investigator
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
James Elder, MD
Role: PRINCIPAL_INVESTIGATOR
Ohio State University Comprehensive Cancer Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University Medical Center
Columbus, Ohio, United States
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
The Jamesline
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NCI-2014-01110
Identifier Type: REGISTRY
Identifier Source: secondary_id
OSU-12161
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.